Related references
Note: Only part of the references are listed.Serum Heparan Sulfate Concentration is Correlated with the Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment in Patients with Lung Adenocarcinoma
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
P. Moreau et al.
LEUKEMIA (2011)
Advances in the preclinical testing of cancer therapeutic hypotheses
Giordano Caponigro et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Molecular Target Class Is Predictive of In vitro Response Profile
Joel Greshock et al.
CANCER RESEARCH (2010)
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Jonathan R. Dry et al.
CANCER RESEARCH (2010)
Clinical Implications of the Cancer Genome
Laura E. MacConaill et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L. Sos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Modeling genomic diversity and tumor dependency in malignant melanoma
William M. Lin et al.
CANCER RESEARCH (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R. Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1:: Role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
WC Guo et al.
CANCER RESEARCH (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Regularization and variable selection via the elastic net
H Zou et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2005)
Chemosensitivity prediction by transcriptional profiling
JE Staunton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Systematic variation in gene expression patterns in human cancer cell lines
DT Ross et al.
NATURE GENETICS (2000)
Share Paper
